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De-escalation of antiplatelet therapy 
— an approach to improve safety and 
efficacy of treatment in patients after 
acute coronary syndrome
Dual antiplatelet treatment (DAPT) with aspirin 
and P2Y12 inhibitor - clopidogrel has been shown to 
reduce the risk of ischaemic events in patients after 
acute coronary syndrome (ACS) [1–3]. Further studies 
proved the superiority of ticagrelor and prasugrel over 
clopidogrel in this clinical setting [4–6]. It has been also 
demonstrated that prolongation of DAPT over one year 
with lower doses of P2Y12 inhibitor may further improve 
clinical outcome in patients with previous ACS [7]. At the 
same time significant improvement in the technology 
of stents and implantable scaffolds, including design, 
materials, and antiproliferative agents, occurred resulting 
in the reduction of thrombogenicity of these devices and 
allowing the safe shortening of DAPT if necessary [8]. 
Moreover, changes of platelet reactivity on treatment with 
P2Y12 inhibitors during the acute phase and the following 
stable period after ACS [9–18] is an additional factor to 
be considered. The complexity and ever-better under-
standing of the pathophysiology of ACS, as well as the 
ever-wider therapeutic possibilities, require a rethinking 
of the antiplatelet treatment strategy in this clinical setting.
According to the current guidelines, DAPT with 
a P2Y12 receptor inhibitor and aspirin is recommended 
for 12 months to reduce adverse thrombotic events [10, 
12, 19, 20]. DAPT can be modified, its duration can 
be shortened or extended depending on the patient’s 
ischaemic and bleeding risk, the occurrence of adverse 
events, comorbidities, co-medications, and drugs avail-
ability [12]. Termination of treatment with aspirin after 
3-6 months after PCI with stent implantation for ACS 
should be considered, depending on the balance be-
tween bleeding and ischaemic risk [19]. De-escalation 
of DAPT defined as replacing prasugrel or ticagrelor 
with clopidogrel may be considered in patients after 
ACS. De-escalation may be unguided, based solely on 
clinical judgment or guided by platelet function testing 
or CYP2C19 genotyping, depending on the patient’s 
risk profile and availability of respective assays [19].
The recommendation regarding the de-escalation 
strategy based on switching a potent P2Y12 receptor 
inhibitor to clopidogrel is based on the TOPIC study and 
the TROPICAL-ACS study [19, 21, 22]. In the TOPIC 
study switching from prasugrel or ticagrelor to clopi-
dogrel one month after ACS was associated with a net 
clinical benefit mainly driven by bleeding reduction with 
an unchanged risk of ischaemic events [21]. The TROP-
ICAL-ACS study showed that de-escalation from pras-
ugrel to clopidogrel guided by platelet function testing 
was non-inferior to standard treatment with prasugrel at 
1 year after percutaneous coronary intervention in terms 
of net clinical benefit in patients with ACS. However, in 
the de-escalation group, as much as 39% of patients 
required a switch-back to prasugrel due to insufficient 
platelet inhibition with clopidogrel defined as HPR [22]. 
The TWILIGHT study tested another de-escalation 
strategy comparing DAPT with ticagrelor 90 mg b.i.d. 
and aspirin versus ticagrelor 90 mg b.i.d. alone was 
assessed [28].  Monotherapy with ticagrelor resulted 
in substantially less bleeding events than DAPT arm 
without ischaemic harm [23].
Recently a new antiplatelet de-escalation approach 
was proposed in the ELECTRA-SIRIO 2 study (Clinical-
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Trials.gov Identifier: NCT04718025; EudraCT number: 
2020-005130-15). The study was designed to evaluate 
the safety and efficacy of ticagrelor dose reduction with 
or without the continuation of aspirin versus DAPT with 
standard-dose ticagrelor in ACS patients. The strategy 
proposed in the ELECTRA-SIRIO 2 study does not 
require platelet reactivity testing, making de-escalation 
more feasible for a wide clinical application [24–28]. 
The study population will comprise 4,500 patients 
consecutively admitted to the study centres due to 
ACS, including patients with ST-elevation myocardial 
infarction, non-ST-elevation myocardial infarction and 
unstable angina [24]. The intention-to-treat analysis, 
i.e. with the inclusion of all patients according to the 
randomly assigned trial group, irrespective of the 
actual treatment received, is a widely used method in 
randomized clinical trials, therefore adherence to study 
medication is a pivotal issue. Poor adherence to the 
study treatment may lead to serious evaluation bias [29, 
30]. The MEDMOTION project involving patients’ edu-
cation, motivation, reminding them to take medications 
and to attend consecutive medical appointments will 
be applied to improve adherence to study medication 
[31–50]. The project includes the diagnosis of study 
participants concerning their readiness for discharge 
from the hospital (the Readiness for Hospital Discharge 
after Myocardial Infarction Scale – RHD-MIS), the risk 
of non-adherence to the medication (the Adherence in 
Chronic Diseases Scale, ACDS), and the functioning in 
disease (the Functioning in Chronic Illness Scale, FCIS). 
A prespecified sub-analysis of the ELECTRA-SIRIO 
2 trial is planned to evaluate the impact of the results of 
MEDMOTION diagnostic tools on the clinical outcomes 
[24, 51–59].
The ELECTRA-SIRIO 2 study testing a new approach 
to treatment de-escalation is expected to provide a new, 
safer, yet easy-to-apply antiplatelet treatment strategy 
in a patient after ACS.
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